HISOAR(SZ:002099) Ge Long Hui A P P·2025-12-17 10:38Core Viewpoint - The company Haisheng Pharmaceutical (002099.SZ) has announced the initiation of Phase II clinical trials for its innovative therapeutic vaccine NWRD08, targeting HPV-related cervical lesions, marking a significant advancement in cancer treatment in China [1][2]. Group 1: Company Announcement - Haisheng Pharmaceutical received a notification from its subsidiary fund management company, Beijing Guoxin Zhongshu Investment Management Co., Ltd., regarding the participation of Guoxin Haisheng in the investment of Nuo Wei Biotechnology (Wuxi) Co., Ltd. [1] - The Phase II clinical trial for NWRD08 has officially started at several hospitals, including Peking Union Medical College Hospital, with the first subject enrolled and treated [1]. Group 2: Product Details - NWRD08 is the first therapeutic nucleic acid drug in China specifically designed for patients with HPV16/18 positive high-grade squamous intraepithelial lesions (HSIL), aiming to activate specific T-cell immunity to eliminate infected cells [2]. - Unlike preventive HPV vaccines, NWRD08 targets patients already infected with HPV and exhibiting related lesions, offering a new treatment approach [2]. - The Phase I clinical study demonstrated excellent safety and efficacy, with over 80% of subjects achieving either pathological downgrade or HPV virus clearance [2]. - NWRD08 provides a systemic immunotherapy option that is easy to administer and has a low recurrence rate, potentially protecting patients from cervical cancer and treating other HPV-related cancers such as anal, vulvar, and head and neck cancers [2].